XyloCor Therapeutics has entered into a licensing agreement with SmartWise, a subsidiary of SmartCella Holding AB, giving XyloCor access to SmartWise's proprietary Extroducer Infusion Catheter System for cardiovascular treatment. The total deal value and mid-single-digit royalties are approximately USD 130 million.
The agreement will allow the use of the Extroducer novel endovascular device to deliver XyloCor’s top gene therapy candidate, XC001, directly to the heart less invasively, reducing possible surgical complications. The therapy aims to decrease the ischemic load by creating new blood vessels to improve blood flow in heart patients suffering from refractory angina.
XyloCor Therapeutics is a biopharmaceutical company specializing in gene therapy for cardiovascular disease, particularly advanced coronary artery disease. Its lead product candidate, XC001 (encoberminogene rezmadenovec), is a single-dose gene therapy currently in clinical development for treating refractory angina, which is a condition characterized by chronic chest pain due to insufficient blood flow to the heart. XyloCor also has a preclinical candidate, XC002, who treats heart attack-related cardiac tissue damage.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.